Cerebral Toxoplasmosis in a Patient with Systemic Sclerosis Under Thalidomide Treatment: A Case Report
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Halonen S, Weiss L
. Toxoplasmosis. Handb Clin Neurol. 2013; 114:125-45.
PMC: 4157368.
DOI: 10.1016/B978-0-444-53490-3.00008-X.
View
2.
Durieux M, Lopez J, Banjari M, Passebosc-Faure K, Brenier-Pinchart M, Paris L
. Toxoplasmosis in patients with an autoimmune disease and immunosuppressive agents: A multicenter study and literature review. PLoS Negl Trop Dis. 2022; 16(8):e0010691.
PMC: 9387931.
DOI: 10.1371/journal.pntd.0010691.
View
3.
DAmato R, Loughnan M, Flynn E, Folkman J
. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994; 91(9):4082-5.
PMC: 43727.
DOI: 10.1073/pnas.91.9.4082.
View
4.
Arnson Y, Amital H, Guiducci S, Matucci-Cerinic M, Valentini G, Barzilai O
. The role of infections in the immunopathogensis of systemic sclerosis--evidence from serological studies. Ann N Y Acad Sci. 2009; 1173:627-32.
DOI: 10.1111/j.1749-6632.2009.04808.x.
View
5.
Offidani M, Corvatta L, Polloni C, Gentili S, Brioni A, Visani G
. Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomide. Leuk Lymphoma. 2011; 52(5):776-85.
DOI: 10.3109/10428194.2011.555027.
View